227 related articles for article (PubMed ID: 25537510)
1. Clinically relevant genes and regulatory pathways associated with NRASQ61 mutations in melanoma through an integrative genomics approach.
Jiang W; Jia P; Hutchinson KE; Johnson DB; Sosman JA; Zhao Z
Oncotarget; 2015 Feb; 6(4):2496-508. PubMed ID: 25537510
[TBL] [Abstract][Full Text] [Related]
2. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
[TBL] [Abstract][Full Text] [Related]
3. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
[TBL] [Abstract][Full Text] [Related]
4. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
[TBL] [Abstract][Full Text] [Related]
5. Differences in microRNA expression between melanoma and healthy adjacent skin.
Aksenenko M; Palkina N; Komina A; Tashireva L; Ruksha T
BMC Dermatol; 2019 Jan; 19(1):1. PubMed ID: 30611259
[TBL] [Abstract][Full Text] [Related]
6. Dual NRASQ61R and BRAFV600E mutation-specific immunohistochemistry completes molecular screening in melanoma samples in a routine practice.
Uguen A; Guéguen P; Legoupil D; Bouvier S; Costa S; Duigou S; Lemasson G; Ledé F; Sassolas B; Talagas M; Férec C; Le Maréchal C; De Braekeleer M; Marcorelles P
Hum Pathol; 2015 Nov; 46(11):1582-91. PubMed ID: 26297254
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
Yaman B; Akalin T; Kandiloğlu G
Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
[TBL] [Abstract][Full Text] [Related]
8. An integrative genomics approach for identifying novel functional consequences of PBRM1 truncated mutations in clear cell renal cell carcinoma (ccRCC).
Wang Y; Guo X; Bray MJ; Ding Z; Zhao Z
BMC Genomics; 2016 Aug; 17 Suppl 7(Suppl 7):515. PubMed ID: 27556922
[TBL] [Abstract][Full Text] [Related]
9. [ Spectrum of oncogene mutations is different in melanoma subtypes].
Mazurenko NN; Tsyganova IV; Lushnikova AA; Ponkratova DA; Anurova OA; Cheremushkin EA; Mikhailova IN; Demidov LV
Mol Biol (Mosk); 2015; 49(6):1022-9. PubMed ID: 26710785
[TBL] [Abstract][Full Text] [Related]
10. NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract--a study of 24 cases from the Netherlands.
van Engen-van Grunsven AC; Küsters-Vandevelde HV; De Hullu J; van Duijn LM; Rijntjes J; Bovée JV; Groenen PJ; Blokx WA
Gynecol Oncol; 2014 Jul; 134(1):10-4. PubMed ID: 24802725
[TBL] [Abstract][Full Text] [Related]
11. NRAS mutations in primary and metastatic melanomas of Japanese patients.
Uhara H; Ashida A; Koga H; Ogawa E; Uchiyama A; Uchiyama R; Hayashi K; Kiniwa Y; Okuyama R
Int J Clin Oncol; 2014; 19(3):544-8. PubMed ID: 23739925
[TBL] [Abstract][Full Text] [Related]
12. NRAS mutant melanoma: Towards better therapies.
Randic T; Kozar I; Margue C; Utikal J; Kreis S
Cancer Treat Rev; 2021 Sep; 99():102238. PubMed ID: 34098219
[TBL] [Abstract][Full Text] [Related]
13. Clonal architectures and driver mutations in metastatic melanomas.
Ding L; Kim M; Kanchi KL; Dees ND; Lu C; Griffith M; Fenstermacher D; Sung H; Miller CA; Goetz B; Wendl MC; Griffith O; Cornelius LA; Linette GP; McMichael JF; Sondak VK; Fields RC; Ley TJ; Mulé JJ; Wilson RK; Weber JS
PLoS One; 2014; 9(11):e111153. PubMed ID: 25393105
[TBL] [Abstract][Full Text] [Related]
14. Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas.
Griewank KG; Westekemper H; Murali R; Mach M; Schilling B; Wiesner T; Schimming T; Livingstone E; Sucker A; Grabellus F; Metz C; Süsskind D; Hillen U; Speicher MR; Woodman SE; Steuhl KP; Schadendorf D
Clin Cancer Res; 2013 Jun; 19(12):3143-52. PubMed ID: 23633454
[TBL] [Abstract][Full Text] [Related]
15. BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage.
Mar VJ; Wong SQ; Li J; Scolyer RA; McLean C; Papenfuss AT; Tothill RW; Kakavand H; Mann GJ; Thompson JF; Behren A; Cebon JS; Wolfe R; Kelly JW; Dobrovic A; McArthur GA
Clin Cancer Res; 2013 Sep; 19(17):4589-98. PubMed ID: 23833303
[TBL] [Abstract][Full Text] [Related]
16. Variation of mutant allele frequency in NRAS Q61 mutated melanomas.
Hélias-Rodzewicz Z; Funck-Brentano E; Terrones N; Beauchet A; Zimmermann U; Marin C; Saiag P; Emile JF
BMC Dermatol; 2017 Jul; 17(1):9. PubMed ID: 28668077
[TBL] [Abstract][Full Text] [Related]
17. Genetic alterations in signaling pathways in melanoma.
Haluska FG; Tsao H; Wu H; Haluska FS; Lazar A; Goel V
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2301s-2307s. PubMed ID: 16609049
[TBL] [Abstract][Full Text] [Related]
18. NRAS and BRAF mutations in cutaneous melanoma and the association with MC1R genotype: findings from Spanish and Austrian populations.
Hacker E; Nagore E; Cerroni L; Woods SL; Hayward NK; Chapman B; Montgomery GW; Soyer HP; Whiteman DC
J Invest Dermatol; 2013 Apr; 133(4):1027-33. PubMed ID: 23096702
[TBL] [Abstract][Full Text] [Related]
19. Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma.
Atefi M; Titz B; Avramis E; Ng C; Wong DJ; Lassen A; Cerniglia M; Escuin-Ordinas H; Foulad D; Comin-Anduix B; Graeber TG; Ribas A
Mol Cancer; 2015 Feb; 14(1):27. PubMed ID: 25645078
[TBL] [Abstract][Full Text] [Related]
20. In-depth genomic data analyses revealed complex transcriptional and epigenetic dysregulations of BRAFV600E in melanoma.
Guo X; Xu Y; Zhao Z
Mol Cancer; 2015 Mar; 14():60. PubMed ID: 25890285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
